Search results for Varlilumab ELISA Kit
Varlilumab ELISA Kit, ProteoGenix, KPTX213
Description of Varlilumab ELISA Kit Introduction Varlilumab is a human monoclonal antibody that is being developed as a potential immunotherapy for the treatment of various types of cancer. It works by targeting and activating a protein called CD27, which is found on the surface of certain immune cells. Varlilumab ELISA (enzyme-linked immunosorbent assay) kit is a specialized tool used to detect and quantify the levels of this antibody in biological samples. In this article, we will discuss the structure, activity, and application of Varlilumab ELISA kit in detail. Structure of Varlilumab ELISA Kit The Varlilumab ELISA kit contains all the necessary components for a standard ELISA assay, including microtiter plates, buffers, standards, and detection reagents. The microtiter plates are coated with a specific antibody that binds to Varlilumab. The samples, along with the standards of known concentrations, are added to the wells and allowed to incubate. If Varlilumab is present in the sample, it will bind to the coated antibody. After washing away any unbound components, a detection antibody is added, which binds to the Varlilumab-antibody complex. This is followed by the addition of a substrate that produces a colorimetric signal in the presence of the detection antibody. The intensity of the color is directly proportional to the amount of Varlilumab present in the sample. Activity of Varlilumab ELISA Kit The Varlilumab ELISA kit is a highly sensitive and specific tool for the detection of Varlilumab in biological samples. It can detect Varlilumab at concentrations as low as 0.1 ng/mL, making it a valuable tool for monitoring the levels of this antibody in patients receiving Varlilumab therapy. The kit also has a wide dynamic range, allowing for the detection of Varlilumab in a variety of sample types, including serum, plasma, and cell culture supernatants. The activity of the Varlilumab ELISA kit is validated by comparing the results obtained with the kit to those obtained with other methods, such as Western blotting or flow cytometry. Application of Varlilumab ELISA Kit The Varlilumab ELISA kit has several applications in both research and clinical settings. In research, it is used to study the pharmacokinetics and pharmacodynamics of Varlilumab, as well as to determine its efficacy in preclinical studies. It can also be used to measure the levels of Varlilumab in patient samples to assess response to treatment and monitor disease progression. In clinical settings, the Varlilumab ELISA kit can be used to select patients who are most likely to benefit from Varlilumab therapy, as well as to monitor the levels of Varlilumab during treatment to ensure optimal dosing. Conclusion In summary, the Varlilumab ELISA kit is a valuable tool for the detection and quantification of Varlilumab in biological samples. Its high sensitivity and specificity make it a reliable method for monitoring Varlilumab therapy in both research and clinical settings. With the increasing interest in immunotherapies for cancer treatment, the Varlilumab ELISA kit is a crucial tool for studying the activity and potential of this promising antibody.
Host
Reactivity
Applications
Conjugation
Varlilumab ELISA Kit, Abbexa, abx395102
Varlilumab ELISA Kit is a quantitative ELISA kit for detection of Varlilumab.Varlilumab (CDX-1127), a human IgG1κ monoclonal antibody, targets CD27 receptor through reacting with the ligand binding site of CD27. CD27 is a member of the tumor necrosis factor receptor superfamily and expressed on unstimulated T lymphocytes, serving as a potent costimulatory molecule. It has been found that CD27 induces a series of T-cell reactions including T-cell activation, proliferation, survival, and maturation of effector capacity and T-cell memory together with its ligand CD70, which is transiently expressed on antigen-presenting cells. Besides, the interaction of CD27 and CD70 also stimulate B-cell proliferation, generation of plasma cells, production of immunoglobulin and B-cell memory, and induction of the cytolytic activity of natural killer (NK) cells. Moreover, CD27 is considered to function on tumor expansion and activation as it also expressed by regulatory T cells (Tregs), a cell that is associated with the suppression of antitumor immunity. The drug, developed by Celldex Therapeutics, is designed for immunotherapy for patients with solid tumors and hematologic malignancies. Varlilumab is currently conducted with two trails. One is the phase 1B clinical trial for advanced breast or ovarian cancer in combination with ONT-10. Another is the phase 1/2 trial for advanced refractory solid tumors together with anti-PD-1 nivolumab.
Host
Reactivity
Human
Applications
ELISA
Conjugation
Please provide the required information below so that we can quickly source your products.